RU2697522C1 - Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака - Google Patents

Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака Download PDF

Info

Publication number
RU2697522C1
RU2697522C1 RU2016124540A RU2016124540A RU2697522C1 RU 2697522 C1 RU2697522 C1 RU 2697522C1 RU 2016124540 A RU2016124540 A RU 2016124540A RU 2016124540 A RU2016124540 A RU 2016124540A RU 2697522 C1 RU2697522 C1 RU 2697522C1
Authority
RU
Russia
Prior art keywords
human
ceacam1
antibody
cancer
binding fragment
Prior art date
Application number
RU2016124540A
Other languages
English (en)
Russian (ru)
Other versions
RU2016124540A (ru
Inventor
Техила БЕН-МОШЕ
Яр САПИР
Илана МЕНДЕЛ
Эдна МЕЙЛИН
Original Assignee
СиСиЭйЭм БАЙОТЕРАПЬЮТИКС ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиСиЭйЭм БАЙОТЕРАПЬЮТИКС ЛТД. filed Critical СиСиЭйЭм БАЙОТЕРАПЬЮТИКС ЛТД.
Publication of RU2016124540A publication Critical patent/RU2016124540A/ru
Application granted granted Critical
Publication of RU2697522C1 publication Critical patent/RU2697522C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016124540A 2013-11-25 2014-11-25 Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака RU2697522C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908190P 2013-11-25 2013-11-25
US61/908,190 2013-11-25
PCT/IL2014/051019 WO2015075725A1 (en) 2013-11-25 2014-11-25 Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy

Publications (2)

Publication Number Publication Date
RU2016124540A RU2016124540A (ru) 2017-12-29
RU2697522C1 true RU2697522C1 (ru) 2019-08-15

Family

ID=53179065

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016124540A RU2697522C1 (ru) 2013-11-25 2014-11-25 Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака

Country Status (13)

Country Link
US (1) US10081679B2 (https=)
EP (2) EP3763387B1 (https=)
JP (2) JP6879739B2 (https=)
KR (1) KR102362803B1 (https=)
CN (1) CN105744955B (https=)
AU (1) AU2014351308B2 (https=)
CA (1) CA2930218C (https=)
ES (2) ES2808684T3 (https=)
HK (1) HK1225998A1 (https=)
MX (1) MX375221B (https=)
PL (2) PL3763387T3 (https=)
RU (1) RU2697522C1 (https=)
WO (1) WO2015075725A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2835019C1 (ru) * 2020-04-24 2025-02-20 Санофи Противоопухолевые комбинации, включающие конъюгаты на основе антитела к ceacam5, трифлуридин и типирацил
US12564642B2 (en) 2020-11-10 2026-03-03 Sanofi CEACAM5 antibody-drug conjugate formulation
US12570761B2 (en) 2012-11-20 2026-03-10 Sanofi Anti-CEACAM5 antibodies and uses thereof

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN106573977B (zh) 2014-04-27 2020-08-07 菲姆威有限公司 针对ceacam1的人源化抗体
US11427647B2 (en) * 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
CN107345969A (zh) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 包含afp、gp73和ceacam1的血清标记物在诊断肝脏疾病中的用途
CN107345968A (zh) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途
EP3560957A4 (en) 2016-11-14 2020-10-21 Dinona ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
CN106957823A (zh) * 2016-12-28 2017-07-18 无锡傲锐东源生物科技有限公司 抗pd‑l2蛋白单克隆抗体及其用途
KR102019913B1 (ko) * 2017-03-24 2019-09-09 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2022513729A (ja) * 2018-12-07 2022-02-09 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体
JP2022514615A (ja) * 2018-12-20 2022-02-14 アルバート アインシュタイン カレッジ オブ メディスン ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法
KR102166982B1 (ko) * 2019-01-24 2020-10-16 가톨릭대학교 산학협력단 간암에서 CEACAM1 및 EpCAM의 상관관계 및 이를 이용한 간암 치료효과에 대한 정보를 제공하는 방법
CN114040799A (zh) * 2019-03-12 2022-02-11 哈佛大学校长及研究员协会 治疗癌症的方法和组合物
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022116079A1 (zh) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 一种抗ceacam5的人源化抗体及其制备方法和用途
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2024100663A1 (en) * 2022-11-10 2024-05-16 Famewave Ltd. Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
AU2023390277A1 (en) * 2022-12-07 2025-05-29 Immuneonco Biopharmaceuticals (Shanghai) Inc. Cancer combination therapy using cd24 antibody and pd-1-pd-l1 pathway blocking antibody
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
WO2024151091A1 (ko) * 2023-01-11 2024-07-18 한국과학기술원 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물
CN121335923A (zh) * 2023-04-13 2026-01-13 苏州逻晟生物医药有限公司 Ceacam1靶向抗体及其用途
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064100A1 (en) * 2009-03-18 2012-03-15 Simon Barry Biomarkers and uses thereof
RU2493256C2 (ru) * 2007-09-04 2013-09-20 Куревак Гмбх Комплексы на основе рнк и катионных пептидов для трансфекции и иммуностимуляции

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
ES2246567T3 (es) 1998-04-15 2006-02-16 Brigham & Womens Hospital Composiciones para receptores inhibidores de celulas t y usos de las mismas.
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
DE102008036127A1 (de) 2008-08-01 2010-02-04 Emitec Gesellschaft Für Emissionstechnologie Mbh Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
DK2424896T3 (en) 2009-04-30 2015-12-14 Tel Hashomer Medical Res Infrastructure & Services Ltd The anti-CEACAM1 antibodies and methods of use thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
CN104853776B (zh) * 2012-10-12 2021-04-09 布里格姆及妇女医院股份有限公司 免疫应答的增强

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2493256C2 (ru) * 2007-09-04 2013-09-20 Куревак Гмбх Комплексы на основе рнк и катионных пептидов для трансфекции и иммуностимуляции
US20120064100A1 (en) * 2009-03-18 2012-03-15 Simon Barry Biomarkers and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570761B2 (en) 2012-11-20 2026-03-10 Sanofi Anti-CEACAM5 antibodies and uses thereof
RU2835019C1 (ru) * 2020-04-24 2025-02-20 Санофи Противоопухолевые комбинации, включающие конъюгаты на основе антитела к ceacam5, трифлуридин и типирацил
US12564642B2 (en) 2020-11-10 2026-03-03 Sanofi CEACAM5 antibody-drug conjugate formulation
RU2850344C1 (ru) * 2020-12-18 2025-11-11 Ламкап Био Бета Лтд Биспецифические антитела против ceacam5 и cd47

Also Published As

Publication number Publication date
AU2014351308A1 (en) 2016-05-05
EP3074035B1 (en) 2020-05-13
CN105744955B (zh) 2020-03-20
AU2014351308B2 (en) 2020-03-05
MX375221B (es) 2025-03-06
BR112016010557A2 (pt) 2017-12-05
JP2020055853A (ja) 2020-04-09
ES2980417T3 (es) 2024-10-01
EP3074035A4 (en) 2017-06-21
ES2808684T3 (es) 2021-03-01
KR102362803B1 (ko) 2022-02-14
CA2930218C (en) 2020-11-17
EP3074035A1 (en) 2016-10-05
US10081679B2 (en) 2018-09-25
CN105744955A (zh) 2016-07-06
WO2015075725A1 (en) 2015-05-28
EP3763387B1 (en) 2024-03-27
PL3074035T3 (pl) 2021-03-08
PL3763387T3 (pl) 2024-07-29
JP6879739B2 (ja) 2021-06-02
CA2930218A1 (en) 2015-05-28
US20170166637A1 (en) 2017-06-15
RU2016124540A (ru) 2017-12-29
MX2016006726A (es) 2016-12-16
HK1225998A1 (zh) 2017-09-22
EP3763387A1 (en) 2021-01-13
KR20160108310A (ko) 2016-09-19
JP2016537383A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
RU2697522C1 (ru) Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака
RU2761352C2 (ru) Комбинация антител cd30xcd16 для терапии с антагонистом pd-1
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
CN110248668B (zh) 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
KR20180011165A (ko) 신생물 치료를 위한 치료적 조합물 및 방법
Baldo Monoclonal antibodies approved for cancer therapy
WO2015198312A1 (en) Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP2024536227A (ja) がんの治療のためのｂ７－ｈ４抗体薬物コンジュゲート
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
WO2015075710A1 (en) Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
BR122022024159B1 (pt) Uso de um anticorpo monoclonal para ceacam1 humana e de um anticorpo monoclonal para pd-l1 humana ou de um fragmento de ligação ao antígeno do mesmo para tratar câncer
BR112016010557B1 (pt) Uso de um anticorpo monoclonal para ceacam1 humana, ou um fragmento de ligação ao antígeno do mesmo e um anticorpo monoclonal para pd-1 humana ou um fragmento de ligação ao antígeno do mesmo e kit
HK40116886A (zh) 用於治疗癌症的包括fas轴拮抗剂和t-reg细胞消耗剂拮抗剂的联合疗法
HK1253022B (zh) Cd30×cd16抗体与pd-1拮抗剂的联合药物
WO2015198311A1 (en) Compositions comprising antibodies to ceacam-1 and kir for cancer therapy

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20210324